Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells
Cédric Menard, Joëlle Dulong, David Roulois et al. · Stem Cells · 2019
Clinical-grade mesenchymal stromal cells (MSCs) can be expanded from bone marrow and adipose tissue to treat inflammatory diseases and degenerative disorders. However, the influence of their tissue of origin on their functional properties, including their immunosuppressive activity, remains unsolved. In this study, we produced paired bone marrow-derived mesenchymal stromal cell (BM-MSC) and adipose-derived stromal cell (ASC) batches from 14 healthy donors. We then compared them using transcriptomic, phenotypic, and functional analyses and validated our results on purified native MSCs to infer which differences were really endowed by tissue of origin. Cultured MSCs segregated together owing to their tissue of origin based on their gene expression profile analyzed using differential expression and weighted gene coexpression network analysis. This translated into distinct immune-related gene signatures, phenotypes, and functional cell interactions. Importantly, sorted native BM-MSCs and ASCs essentially displayed the same distinctive patterns than their in vitro-expanded counterparts. As a whole, ASCs exhibited an immune profile consistent with a stronger inhibition of immune response and a lower immunogenicity, supporting the use of adipose tissue as a valuable source for clinical applications.
Cited by 101 works. doi:10.1002/stem.3077 Open-access PDF
Authors
- Cédric Menard
- Joëlle Dulong
- David Roulois
- Benjamin Hébraud
- Léa Verdière
- Céline Pangault
- Vonick Sibut
- Isabelle Bézier
- Nadège Bescher
- Céline Monvoisin
- Mélanie Gadelorge
- Nicolas Bertheuil
- Erwan M. Flecher
- Louis Casteilla
- Philippe Collas
- Luc Sensebé
- Philippe Bourin
- Nicolas Espagnolle
- Karin Tarte
References
- WGCNA: an R package for weighted correlation network analysis
- Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
- Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
- Mesenchymal stem cells: immune evasive, not immune privileged
- Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases
- Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages
- Human MSC Suppression Correlates With Cytokine Induction of Indoleamine 2,3-Dioxygenase and Bystander M2 Macrophage Differentiation
- The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?
- MSC-Based Product Characterization for Clinical Trials: An FDA Perspective
- Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks